A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL
Status:
Unknown status
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
Metformin is an antidiabetic drug which is an inexpensive and generally well tolerated
medication. More recently metformin has been shown to act against carcinomas by two
mechanisms: 1) an indirect, insulin-dependent mechanism which sensitizes tissues to insulin,
inhibits hepatic gluconeogenesis, and stimulates uptake of glucose in muscle, thereby
reducing fasting blood glucose and circulating levels of insulin, lowering the pro survival
activity of the insulin/INSR axis, and 2) a direct, insulin-independent mechanism which
activates the AMP-activated protein kinase (AMPK) pathway and leads to inhibition of the mTOR
pathway. Given the investigators preliminary published data on insulin and mTOR inhibition[1]
metformin is an attractive candidate for a pilot clinical trial in CLL patients.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center